331 related articles for article (PubMed ID: 32438039)
1. Pseurotin A as a novel suppressor of hormone dependent breast cancer progression and recurrence by inhibiting PCSK9 secretion and interaction with LDL receptor.
Abdelwahed KS; Siddique AB; Mohyeldin MM; Qusa MH; Goda AA; Singh SS; Ayoub NM; King JA; Jois SD; El Sayed KA
Pharmacol Res; 2020 Aug; 158():104847. PubMed ID: 32438039
[TBL] [Abstract][Full Text] [Related]
2. Pseurotin A Validation as a Metastatic Castration-Resistant Prostate Cancer Recurrence-Suppressing Lead via PCSK9-LDLR Axis Modulation.
Abdelwahed KS; Siddique AB; Ebrahim HY; Qusa MH; Mudhish EA; Rad AH; Zerfaoui M; Abd Elmageed ZY; El Sayed KA
Mar Drugs; 2023 Mar; 21(4):. PubMed ID: 37103355
[TBL] [Abstract][Full Text] [Related]
3. Towards Developing Novel Prostate Cancer Recurrence Suppressors: Acute Toxicity of Pseurotin A, an Orally Active PCSK9 Axis-Targeting Small-Molecule in Swiss Albino Mice.
McGehee OC; Ebrahim HY; Rad AH; Abdelwahed KS; Mudhish EA; King JA; Helal IE; Meyer SA; El Sayed KA
Molecules; 2023 Feb; 28(3):. PubMed ID: 36771126
[TBL] [Abstract][Full Text] [Related]
4. PCSK9 Axis-Targeting Pseurotin A as a Novel Prostate Cancer Recurrence Suppressor Lead.
Abdelwahed KS; Siddique AB; Qusa MH; King JA; Souid S; Abd Elmageed ZY; El Sayed KA
ACS Pharmacol Transl Sci; 2021 Dec; 4(6):1771-1781. PubMed ID: 34927009
[TBL] [Abstract][Full Text] [Related]
5. Cyclase-associated protein 1 is a binding partner of proprotein convertase subtilisin/kexin type-9 and is required for the degradation of low-density lipoprotein receptors by proprotein convertase subtilisin/kexin type-9.
Jang HD; Lee SE; Yang J; Lee HC; Shin D; Lee H; Lee J; Jin S; Kim S; Lee SJ; You J; Park HW; Nam KY; Lee SH; Park SW; Kim JS; Kim SY; Kwon YW; Kwak SH; Yang HM; Kim HS
Eur Heart J; 2020 Jan; 41(2):239-252. PubMed ID: 31419281
[TBL] [Abstract][Full Text] [Related]
6. In silico Screening of Chemical Libraries to Develop Inhibitors That Hamper the Interaction of PCSK9 with the LDL Receptor.
Min DK; Lee HS; Lee N; Lee CJ; Song HJ; Yang GE; Yoon D; Park SW
Yonsei Med J; 2015 Sep; 56(5):1251-7. PubMed ID: 26256967
[TBL] [Abstract][Full Text] [Related]
7. A small molecule inhibitor of PCSK9 that antagonizes LDL receptor binding via interaction with a cryptic PCSK9 binding groove.
Evison BJ; Palmer JT; Lambert G; Treutlein H; Zeng J; Nativel B; Chemello K; Zhu Q; Wang J; Teng Y; Tang W; Xu Y; Rathi AK; Kumar S; Suchowerska AK; Parmar J; Dixon I; Kelly GE; Bonnar J
Bioorg Med Chem; 2020 Mar; 28(6):115344. PubMed ID: 32051094
[TBL] [Abstract][Full Text] [Related]
8. Activation of Adiponectin Receptor Regulates Proprotein Convertase Subtilisin/Kexin Type 9 Expression and Inhibits Lesions in ApoE-Deficient Mice.
Sun L; Yang X; Li Q; Zeng P; Liu Y; Liu L; Chen Y; Yu M; Ma C; Li X; Li Y; Zhang R; Zhu Y; Miao QR; Han J; Duan Y
Arterioscler Thromb Vasc Biol; 2017 Jul; 37(7):1290-1300. PubMed ID: 28546220
[TBL] [Abstract][Full Text] [Related]
9. microRNA-483 ameliorates hypercholesterolemia by inhibiting PCSK9 production.
Dong J; He M; Li J; Pessentheiner A; Wang C; Zhang J; Sun Y; Wang WT; Zhang Y; Liu J; Wang SC; Huang PH; Gordts PL; Yuan ZY; Tsimikas S; Shyy JY
JCI Insight; 2020 Dec; 5(23):. PubMed ID: 33119548
[TBL] [Abstract][Full Text] [Related]
10. Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Single Domain Antibodies Are Potent Inhibitors of Low Density Lipoprotein Receptor Degradation.
Weider E; Susan-Resiga D; Essalmani R; Hamelin J; Asselin MC; Nimesh S; Ashraf Y; Wycoff KL; Zhang J; Prat A; Seidah NG
J Biol Chem; 2016 Aug; 291(32):16659-71. PubMed ID: 27284008
[TBL] [Abstract][Full Text] [Related]
11. In vitro selection generates RNA aptamer that antagonizes PCSK9-LDLR interaction and recovers cellular LDL uptake.
Ando T; Yamamoto M; Yokoyama T; Horiuchi D; Kawakami T
J Biosci Bioeng; 2021 Mar; 131(3):326-332. PubMed ID: 33177004
[TBL] [Abstract][Full Text] [Related]
12. Liraglutide downregulates hepatic LDL receptor and PCSK9 expression in HepG2 cells and db/db mice through a HNF-1a dependent mechanism.
Yang SH; Xu RX; Cui CJ; Wang Y; Du Y; Chen ZG; Yao YH; Ma CY; Zhu CG; Guo YL; Wu NQ; Sun J; Chen BX; Li JJ
Cardiovasc Diabetol; 2018 Apr; 17(1):48. PubMed ID: 29618348
[TBL] [Abstract][Full Text] [Related]
13. Asialoglycoprotein receptor 1 is a novel PCSK9-independent ligand of liver LDLR cleaved by furin.
Susan-Resiga D; Girard E; Essalmani R; Roubtsova A; Marcinkiewicz J; Derbali RM; Evagelidis A; Byun JH; Lebeau PF; Austin RC; Seidah NG
J Biol Chem; 2021 Oct; 297(4):101177. PubMed ID: 34508778
[TBL] [Abstract][Full Text] [Related]
14. Ser-Phosphorylation of PCSK9 (Proprotein Convertase Subtilisin-Kexin 9) by Fam20C (Family With Sequence Similarity 20, Member C) Kinase Enhances Its Ability to Degrade the LDLR (Low-Density Lipoprotein Receptor).
Ben Djoudi Ouadda A; Gauthier MS; Susan-Resiga D; Girard E; Essalmani R; Black M; Marcinkiewicz J; Forget D; Hamelin J; Evagelidis A; Ly K; Day R; Galarneau L; Corbin F; Coulombe B; Çaku A; Tagliabracci VS; Seidah NG
Arterioscler Thromb Vasc Biol; 2019 Oct; 39(10):1996-2013. PubMed ID: 31553664
[TBL] [Abstract][Full Text] [Related]
15. Polydatin ameliorates low-density lipoprotein cholesterol and lipid metabolism by downregulating proprotein convertase subtilisin/kexin type 9 (PCSK9) in triple-negative breast cancer with hyperlipidemia.
Liu M; Zhang Q
Am J Cancer Res; 2024; 14(1):52-72. PubMed ID: 38323270
[TBL] [Abstract][Full Text] [Related]
16. Hepatic overexpression of idol increases circulating protein convertase subtilisin/kexin type 9 in mice and hamsters via dual mechanisms: sterol regulatory element-binding protein 2 and low-density lipoprotein receptor-dependent pathways.
Sasaki M; Terao Y; Ayaori M; Uto-Kondo H; Iizuka M; Yogo M; Hagisawa K; Takiguchi S; Yakushiji E; Nakaya K; Ogura M; Komatsu T; Ikewaki K
Arterioscler Thromb Vasc Biol; 2014 Jun; 34(6):1171-8. PubMed ID: 24675665
[TBL] [Abstract][Full Text] [Related]
17. 23,24-Dihydrocucurbitacin B promotes lipid clearance by dual transcriptional regulation of LDLR and PCSK9.
Li HH; Li J; Zhang XJ; Li JM; Xi C; Wang WQ; Lu YL; Xuan LJ
Acta Pharmacol Sin; 2020 Mar; 41(3):327-335. PubMed ID: 31358898
[TBL] [Abstract][Full Text] [Related]
18. An Unbiased Mass Spectrometry Approach Identifies Glypican-3 as an Interactor of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) and Low Density Lipoprotein Receptor (LDLR) in Hepatocellular Carcinoma Cells.
Ly K; Essalmani R; Desjardins R; Seidah NG; Day R
J Biol Chem; 2016 Nov; 291(47):24676-24687. PubMed ID: 27758865
[TBL] [Abstract][Full Text] [Related]
19. Identification of a PCSK9-LDLR disruptor peptide with in vivo function.
Brousseau ME; Clairmont KB; Spraggon G; Flyer AN; Golosov AA; Grosche P; Amin J; Andre J; Burdick D; Caplan S; Chen G; Chopra R; Ames L; Dubiel D; Fan L; Gattlen R; Kelly-Sullivan D; Koch AW; Lewis I; Li J; Liu E; Lubicka D; Marzinzik A; Nakajima K; Nettleton D; Ottl J; Pan M; Patel T; Perry L; Pickett S; Poirier J; Reid PC; Pelle X; Seepersaud M; Subramanian V; Vera V; Xu M; Yang L; Yang Q; Yu J; Zhu G; Monovich LG
Cell Chem Biol; 2022 Feb; 29(2):249-258.e5. PubMed ID: 34547225
[TBL] [Abstract][Full Text] [Related]
20. Identification of neolignans with PCSK9 downregulatory and LDLR upregulatory activities from Penthorum chinense and the potential in cholesterol uptake by transcriptional regulation of LDLR via SREBP2.
Chae HS; Pel P; Cho J; Kim YM; An CY; Huh J; Choi YH; Kim J; Chin YW
J Ethnopharmacol; 2021 Oct; 278():114265. PubMed ID: 34111537
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
